AKT1 and cancer: MK-2206 (Merck & Co., Inc.)is a strong allosteric AKT inhibitor of the 1/2/3 isoforms [211] and has shown encouraging results in studies performed on human pancreatic cancer cell lines Mia PaCa-2 and Panc-1, not only inhibiting cell proliferation and promoting cancer cell apoptosis but also augmenting the cytotoxic effect of chemotherapy when administered in combination with gemcitabine [212].